Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats

Cellular Physiology and Biochemistry

Volumn 36, Issue 4, 2015, Pages 1453-1466

  Cezar, Marcelo D M ^a   Damatto, Ricardo L ^a   Pagan, Luana U ^a   Lima, Aline R R ^a   Martinez, Paula F ^b   Bonomo, Camila ^a   Rosa, Camila M ^a   Campos, Dijon H S ^a   Cicogna, Antonio C ^a   Gomes, Mariana J ^a   Oliveira, Silvio A ^b   Blotta, Daniella A ^a   Okoshi, Marina P ^a   Okoshi, Katashi ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

Aldosterone antagonist; Cardiac remodeling; Collagen; Papillary muscle; Spontaneously hypertensive rat; Ventricular function

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; PROTEIN LYSINE 6 OXIDASE; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE TENSION; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; WISTAR KYOTO RAT; ANIMAL; CARDIAC MUSCLE; COMPLICATION; DRUG EFFECTS; FIBROSIS; HEART; HEART FAILURE; HYPERTENSION; PATHOLOGY;

RATTUS;

ANIMALS; FIBROSIS; HEART; HEART FAILURE; HYPERTENSION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIUM; RATS, INBRED SHR; RATS, INBRED WKY; SPIRONOLACTONE;

EID: 84936971588     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430310     Document Type: Article

References (51)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, J. A. H, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB: Heart disease and stroke statistics-2014 update: A report from the american heart association. Circulation 2014;129:e28-e292.
2. Bing OHL, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH: The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol 1995;27: 383-396.
3. Cicogna AC, Robinson KG, Conrad CH, Singh K, Squire R, Okoshi MP, Bing OHL: Direct effects of colchicine on myocardial function. Studies in hypertrophied and failing spontaneously hypertensive rats. Hypertension 1999;33:60-65.
4. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure: Mol Cell Endocrinol 2012;350:266-272.
5. Mihailidou AS. Aldosterone in heart disease. Curr Hypertens Rep. 2012;14:125-129.
6. Okoshi MP, Yan X, Okoshi K, Nakayama M, Schuldt AJT, O'Connell T, Simpson PC, Lorell BH: Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail 2004;10:511-518.
7. Nolly MB, Caldiz CI, Yeves AM, Villa-Abrille MC, Morgan PE, Amado Mondaca N, Portiansky EL, Chiappe de Cingolani GE, Cingolani HE, Ennis IL: The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium. J Mol Cell Cardiol 2014; 67:60-68.
8. Cheema Y, Zhao W, Zhao T, Khan MU, Green KD, Ahokas RA, Gerling IC, Bhattacharya SK, Weber KT: Reverse remodeling and recovery from cachexia in rats with aldosteronism. Am J Physiol Heart Circ Physiol 2012;303:H486-H495.
9. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, Nishikawa S, Yamanaka S, Matoba S, Kobara M, Tanaka H, Shirayama T, Takamatsu T, Nozawa Y, Matsubara H: Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 2004;110:317-323.
10. Struthers AD, MacDonald TM: Review of aldosterone-and angiotensin ii-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-670.
11. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, Rooijen N, Ertl G, Bauersachs J: Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension 2008;51:905-914.
12. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F: Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005;111:420-427.
13. Martin-Fernandez B, de Las Heras N, Miana M, Ballesteros S, Valero-Munoz M, Vassallo D, Davel AP, Rossoni LV, Cachofeiro V, Lahera V: Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: Involvement of sgk-1. Exp Physiol 2012;97:710-718.
14. Veliotes DG, Norton GR, Correia RJ, Strijdom H, Badenhorst D, Brooksbank R, Woodiwiss AJ: Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats. J Cardiovasc Pharmacol 2010;56:203-211.
15. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H: Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006;47:671-679.
16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
17. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study (rales) investigators. N Engl J Med 1999;341:709-717.
18. Zannad F, McMurray JV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B: Eplerenone in patients with systolic heart failure and mild symptoms. Emphasis-hf study group. N Engl J Med 2011;364:11-21.
19. Vizzardi E, Nodari S, Caretta G, D'Aloia A, Pezzali N, Faden G, Lombardi C, Raddino R, Metra M, Dei Cas L: Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci 2014;347:271-276.
20. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM: Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392.
21. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B: Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The aldo-dhf randomized controlled trial. JAMA 2013;309:781-791.
22. Damatto RL, Martinez PF, Lima AR, Cezar MD, Campos DH, Oliveira SAJ, Guizoni DM, Bonomo C, Nakatani BT, Dal Pai Silva M, Carvalho RF, Okoshi K, Okoshi MP: Heart failure-induced skeletal myopathy in spontaneously hypertensive rats. Int J Cardiol 2013;167:698-703.
23. Cezar MD, Damatto RL, Martinez PF, Lima AR, Campos DH, Rosa CM, Guizoni DM, Bonomo C, Cicogna AC, Gimenes R, Pagan LU, Okoshi MP, Okoshi K: Aldosterone blockade reduces mortality without changing cardiac remodeling in spontaneously hypertensive rats. Cell Physiol Biochem 2013;32:1275-1287.
24. Munoz-Pacheco P, Ortega-Hernandez A, Caro-Vadillo A, Casanueva-Eliceiry S, Aragoncillo P, Egido J, Fernandez-Cruz A, Gomez-Garre D: Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure. J Hypertens 2013;31:2309-2318.
25. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL: Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation 1995;91:161-170.
26. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, Janicki JS: The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006;30:604-610.
27. Mukherjee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res 1990;67:1474-1480.
28. Martinez PF, Okoshi K, Zornoff LA, Oliveira SAJ, Campos DH, Lima AR, Damatto RL, Cezar MD, Bonomo C, Guizoni DM, Padovani CR, Cicogna AC, Okoshi MP: Echocardiographic detection of congestive heart failure in postinfarction rats. J Appl Physiol 2011;111:543-551.
29. Lima AR, Martinez PF, Okoshi K, Guizoni DM, Zornoff LA, Campos DH, Oliveira SAJ, Bonomo C, Pai-Silva MD, Okoshi MP: Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure. Int J Exp Path 2010;91:54-62.
30. Okoshi K, Matsubara LS, Okoshi MP, Cicogna AC, Fioretto JR, Padovani CR, Aragon FF, Matsubara BB: Food restriction-induced myocardial dysfunction demonstrated by the combination of in vivo and in vitro studies. Nutr Res 2002;22:1353-1364.
31. Okoshi K, Fioretto JR, Okoshi MP, Cicogna AC, Aragon FF, Matsubara LS, Matsubara BB: Food restriction induces in vivo ventricular dysfunction in spontaneously hypertensive rats without impairment of in vitro myocardial contractility. Braz J Med Biol Res 2004;37:607-613.
32. Lima AR, Martinez PF, Damatto RL, Cezar MD, Guizoni DM, Bonomo C, Oliveira SA Jr, Dal-Pai Silva M, Zornoff LA, Okoshi K, Okoshi MP: Heart failure-induced diaphragm myopathy. Cell Physiol Biochem 2014;34:333-345.
33. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MSJ, Stewart WJ: Recommendations for chamber quantification: A report from the american society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr 2005;18:1440-1463.
34. Okoshi MP, Okoshi K, Pai VD, Pai-Silva MD, Matsubara LS, Cicogna AC: Mechanical, biochemical, and morphological changes in the heart from chronic food restricted rats. Can J Physiol Pharmacol 2001;79:754-760.
35. Cicogna AC, Padovani CR, Okoshi K, Matsubara LS, Aragon FF, Okoshi MP: The influence of temporal food restriction on the performance of isolated cardiac muscle. Nutr Res 2001;21:639-648.
36. Gut AL, Okoshi MP, Padovani CR, Aragon FF, Cicogna AC: Myocardial dysfunction induced by food restriction is related to calcium cycling and beta-adrenergic system changes. Nutr Res 2003;23:911-919.
37. Fioretto JR, Queiroz SS, Padovani CR, Matsubara LS, Okoshi K, Matsubara BB: Ventricular remodeling and diastolic myocardial dysfunction in rats submitted to protein-calorie malnutrition. Am J Physiol 2002;282:H1327-H1333.
38. Yan X, Schuldt AJ, Price RL, Amende I, Liu FF, Okoshi K, Ho KK, Pope AJ, Borg TK, Lorell BH, Morgan JP: Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing at2 receptors in ventricular myocytes. Am J Physiol Heart Circ Physiol 2008;294:1274-1281.
39. Nascimento AF, Luvizotto RA, Leopoldo AS, Lima-Leopoldo AP, Seiva FR, Justulin LAJ, Silva MD, Okoshi K, Wang XD, Cicogna AC: Long-term high-fat diet-induced obesity decreases the cardiac leptin receptor withou apparent lipotoxicity. Life Sci 2011;88:1031-1038.
40. Alesutan I, Feger M, Pakladok T, Mia S, Ahmed MS, Voelkl J, Lang F: 25-Hydroxyvitamin D3 1-hydroxylase-dependent stimulation of renal klotho expression by spironolactone. Kidney Blood Press Res 2013;37:475-487.
41. Chen X, Cai J, Zhou X, Chen L, Gong Y, Gao Z, Zhang H, Huang W, Zhou H: Protective effect of spironolactone on endothelial-to-mesenchymal transition in HUVECs via notch pathway. Cell Physiol Biochem 2015;36:191-200.
42. Cicogna AC, Padovani CR, Okoshi K, Aragon FF, Okoshi MP: Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle. Am J Med Sci 2000;320:244-248.
43. Okoshi MP, Okoshi K, Matsubara LS, Pai-Silva MD, Gut AL, Padovani CR, Pai VD, Cicogna AC: Myocardial remodeling and dysfunction are induced by chronic food restriction in spontaneously hypertensive rats. Nutr Res 2006;26:567-572.
44. Bing OHL, Wiegner AW, Brooks WW, Fishbein MC, Pfeffer JM: Papillary muscle structure-function relations in the aging spontaneously hypertensive rat. Clin Exper Hyper-Theory and Practice 1988;10:37-58.
45. Baldo MP, Forechi L, Morra EA, Zaniqueli D, Machado RC, Lunz W, Rodrigues SL, Mill JG: Long-term use of low-dose spironolactone in spontaneously hypertensive rats: Effects on the left ventricular hypertrophy and stiffness. Pharmacol Rep 2011;63:975-982.
46. Kambara A, Holycross BJ, Wung P, Schanbacher B, Ghosh S, McCune SA, Bauer JA, Kwiatkowski P: Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. J Cardiovasc Pharmacol 2003;41:830-837.
47. Vizzardi E, Regazzoni V, Caretta G, Gavazzoni M, Sciatti E, Bonadei I, Trichaki E, Raddino R, Metra M: Mineralocorticoid receptor antagonist in heart failure: past, present and future perspectives. IJC Heart & Vessels 2014;3:6-14.
48. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34.
49. Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012;5:5-15.
50. Lopez B, Gonzalez A, Hermida N, Valencia F, de Teresa E, Diez J: Role of lysyl oxidase in myocardial fibrosis: From basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299:H1-H9.
51. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-2706.